1 Treatment-seeking for children with suspected severe malaria attending community

2 health workers and primary health centres in Adamawa State, Nigeria

- Tristan T. Lee^{1,2,#}, Elizabeth Omoluabi^{3,#,*}, Kazeem Ayodeji³, Ocheche Yusuf³, Charles Okon³, 3
- Nina C. Brunner^{1,2}, Giulia Delvento^{1,2}, Aita Signorell^{1,2}, Mark Lambiris^{1,2}, Marek Kwiatkowski^{1,2}, 4
- Christian Burri^{1,2}, Christian Lengeler^{1,2}, Emmanuel Emedo⁴, Fatima Cheshi⁴, Manuel W. 5
- 6 Hetzel^{1,2}
- 7 ¹ Swiss Tropical and Public Health Institute, Basel, Switzerland
- 8 ² University of Basel, Basel, Switzerland
- 9 ³Akena Associates, Abuja, Nigeria
- 10 ⁴ UNICEF, New York, NY, USA
- 11
- 12 [#] Contributed equally
- * Corresponding author: elizomoluabi@akenaresearch.com 13

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

14 Abstract

Background: The Community Access to Rectal Artesunate for Malaria project investigated the feasibility of introducing pre-referral rectal artesunate into existing community-based health services. In that study, the case fatality rate of children visiting primary health centres (PHCs) was 19% compared to 6% in children first visiting community health workers, locally called Community Oriented Resource Persons (CORPs). As case management practices did not fully explain this finding, this publication investigates other reasons underlying the observed difference in case fatality.

Methods: The observational study enrolled 589 children under the age of five years with fever and danger signs indicative of severe malaria attending CORPs and PHCs in Adamawa State, Nigeria, between June 2018 and July 2020. After 28 days, follow-up visits were conducted with caregivers to understand background characteristics, severity of symptoms, home treatment administration, and treatment seeking practices during the child's illness. These factors were compared between children visiting CORPs versus those visiting PHCs as their first health provider.

29 **Results:** Children visiting PHCs were more likely to display danger signs indicative of central 30 nervous system involvement (90% vs. 74%, p < 0.01) and have four or more danger signs 31 (50% vs. 39%, p = 0.02). The delay between illness onset and visiting the community-based 32 provider did not differ between children attending a CORP and children attending a PHC. PHC 33 attendances more often lived in urban areas (16% vs 4%, p=0.01) and travelled farther to their 34 first health provider, which was usually a community-based provider. Although practicing home 35 treatment was common, especially among children attending PHCs (42% vs 33%, p=0.04), 36 almost none of the children were given an antimalarial. PHCs were visited for their 37 professionalism and experience while CORPs were visited for their low cost and because 38 caregivers personally knew and trusted the provider.

Conclusions: Our comparison of children with suspected severe malaria seeking care from
two kinds of community-based health care providers in Nigeria suggest that illness severity
may be the primary driver behind the observed difference in case fatality rate.

42 Keywords: treatment seeking, primary health care, severe febrile illness, malaria

43 Background

Uncomplicated malaria can quickly progress to severe malaria and death if left untreated (1-3). Therefore, early diagnosis and prompt, effective treatment are essential to further reduce malaria mortality (4). Treatment of uncomplicated malaria is generally provided by primary health centres (PHC) and, in several countries in sub-Saharan Africa and beyond, by community health workers implementing the integrated community case management (iCCM) strategy (5).

Health workers at that level can conduct a malaria rapid diagnostic test (mRDT) or sometimes perform microscopy diagnosis of malaria, and provide oral artemisinin-based combination therapy (ACT) to children with uncomplicated malaria. Children with severe malaria have to be referred to health centres or hospitals with inpatient facilities that can manage severe malaria comprehensively. These referral facilities are often more difficult to reach, particularly for communities in remote rural areas.

In 2018 the World Health Organization (WHO) granted pre-qualification to two products of rectal artesunate (RAS) that could be used as a pre-referral treatment for cases of suspected severe malaria in children diagnosed at community level (6). In a clinical trial, pre-referral RAS was shown to reduce death or permanent disability when administered to children under the age of six years with suspected severe malaria who delayed referral to a higher level health facility (7).

62 Nigeria accounts for 27% of the world's malaria cases and 23% of malaria deaths (8). In 63 addition to having the world's highest burden of malaria, the country is also challenged with 64 high levels of poverty, a large rural population with few transportation options, and a poorly 65 functioning health system (9). This situation makes prompt and appropriate treatment seeking 66 for severe malaria difficult to achieve in many places. Considering the potential of RAS to 67 improve children's health outcomes in such a context, pre-referral RAS was added to the treatment guidelines of local community-based providers, including community health workers 68 69 implementing iCCM, known locally as Community Oriented Resource Persons (CORPs), and 70 primary health centers (PHCs) implementing the integrated management of childhood 71 illnesses (IMCI). Even though the national treatment guidelines had already included RAS as 72 pre-referral treatment option before the WHO pre-qualification (10), RAS was not widely used 73 and not at all provided by CORPs.

In an observational study, the Community Access to Rectal Artesunate for Malaria (CARAMAL)
project investigated the health impact of introducing RAS in remote populations in the
Democratic Republic of the Congo, Nigeria, and Uganda (11). In Nigeria, the study did not find

77 a positive health effect of introducing pre-referral RAS in three Local Government Areas (LGA) 78 of Adamawa State. The case fatality rate (CFR) among children with suspected severe malaria 79 during pre and post-RAS implementation phases were 4.2% and 16.1%, respectively. 80 Meanwhile, the study found that the CFR was higher in children first attending a PHC (18.5%) compared to those first attending a CORP (5.7%). These differences in CFR may be 81 attributable to factors such as the health condition at the time of treatment seeking, care 82 83 seeking practices, and treatments provided. Two critical aspects of the continuum of care for 84 severe malaria cases, namely referral completion and post-referral treatment, have been 85 described in other manuscripts (Signorell et al, manuscript in preparation, (12)). But neither 86 seem to provide an explanation of the difference in CFR between the two groups of patients 87 (11).

88 Understanding the reasons underlying these differences in CFR is crucial to ensure that 89 appropriate measures are taken to reduce child deaths at each level of care. In this article, we 90 therefore investigate whether there are underlying differences between children who visited CORPs and those who visited PHCs as community level providers. Currently, the literature 91 92 lacks studies comparing the characteristics of children seeking treatment from different community-based providers. We specifically focused on the severity of symptoms, home 93 94 treatment and treatment seeking delay, while taking into account background characteristics 95 of the patients.

96 <u>Methods</u>

97 Study design

98 This research was conducted as part of the CARAMAL project that accompanied the roll-out 99 of pre-referral RAS into existing iCCM and IMCI systems. The complete methods are detailed 100 elsewhere (Lengeler et al., manuscript in preparation, (11)). This analysis includes children 101 with suspected severe malaria enrolled by community-based providers (CORPs or PHCs) in 102 Nigeria.

103 Setting

Data was collected in Fufore, Mayo-Belwa and Song LGAs of Adamawa State in northeastern Nigeria. The estimated total population of these LGAs was 746,949 in 2018, of which 130,430 (17%) were under the age of five years (13). The population in the three LGAs is served by over 500 CORPs, 77 PHCs, and 3 referral health facilities (Cottage Hospitals). In the study area, malaria occurs seasonally.

109 CORPs and PHCs provide primary health care services at community level. Both use similar 110 guidelines for the assessment and treatment of childhood illnesses, with CORPs implementing 111 iCCM and PHCs implementing IMCI guidelines. PHCs are small health facilities with nurses 112 and intermediate staff. These staff have an educational background in health, in contrast to 113 CORPs who may not have a medical background. CORPs are provided with medical supplies 114 and supervision through nearby PHCs. CORPs were introduced in 2014 to fill an accessibility 115 gap and were placed in communities more than 5 km away from a health facility and in 116 communities hard to reach due to bad road conditions, or natural barriers like rivers and 117 mountains.

118 Data collection

119 Children under five years visiting a PHC or a CORP with a history of fever and at least one 120 danger sign indicative of suspected severe malaria according to Nigerian iCCM guidelines 121 (unusually sleepy or unconscious, not able to drink or feed, vomiting everything, convulsions, 122 or yellow eyes) were enrolled between June 2018 and July 2020. CARAMAL staff attempted 123 to reach community-based providers weekly by phone calls or text message to identify and 124 register children meeting the inclusion criteria. Follow-up visits were done 28 days later in 125 person at the child's residence, or by phone during the COVID-19 pandemic lockdown. 126 Caregiver interviews were conducted in the local language (Hausa or Fulfulde) to collect 127 information about the child's health status, signs and symptoms of disease, treatment seeking 128 perceptions and practices, and medicines the child received. Geolocations of the child's house 129 were recorded. Children who died were followed up two to three months after enrolment to 130 respect the mourning period. Additional details about the circumstances of the death were 131 asked. Data was collected electronically on tablets using ODK Collect, and saved on a 132 password protected ODK Aggregate server hosted at the Swiss Tropical and Public Health 133 Institute in Switzerland.

134 Data analysis

Study participants were included in the analysis if they were successfully followed-up on day 28, their caregiver provided consent, and children were under the age of five, had a history of fever and a Nigeria specific iCCM danger sign, and had a positive mRDT test at enrolment. For consistency with complementary publications (11), children who died after more than 31 days were excluded from the analysis.

This study compares children attending a CORP with children attending a PHC. The main variables of interest were background characteristics, home treatment, treatment seeking delay, disease severity and reasons for going to the CORP or the PHC. Treatment seeking delay was defined as the reported number of days between illness onset and attending the

144 CORP or PHC, categorized into two-day periods. We used the presence of danger signs 145 involving the central nervous system (convulsions, unusually sleepy or unconscious), number 146 of danger signs (out of convulsions, unusually sleepy or unconscious, vomits everything, 147 unable to drink or feed, unable to sit or stand, blood in stool, swelling of both feet), and 148 caregiver-perceived severity as proxies for disease severity. RAS implementation started in 149 May 2019. COVID-19 movement restrictions were in place between April 1, 2020 and the end 150 of the study. The rainy season usually lasts from May to October, and was defined as such. 151 Living in a rural or urban setting was determined based on the child's residence geolocation 152 and the LandScan HD: Nigeria version 1.1 geodatabase (Oak Ridge National Laboratory, 153 2018) per settlement patterns defined by Weber et al. (14).

154 Descriptive analyses comparing CORP and PHC attendance were done using logistic 155 regression models with clustered standard errors (clustering at the level of the enrolling health 156 care provider). These were adjusted for the effect of the COVID-19 pandemic as the pandemic 157 was likely to affect treatment seeking. P-values were calculated using the likelihood ratio test for categorical variables and on the odds ratio for binary variables. P-values of <0.05 were 158 159 considered statistically significant. Unadjusted models, sensitivity analysis using Generalized 160 Estimating Equations, and a further explanation on statistical methods are presented in the 161 supplementary materials. Statistical analyses were conducted in Stata SE version 16.1.

162 **Results**

163 Study population

164 CORPs and PHCs provisionally enrolled 724 children. Of those, 66 (9%) were lost to follow-165 up or the caregiver did not provide consent. We excluded another 69 (10%) children due to 166 children not having a history of fever (n=7), no danger sign (n=26), dying > 31 days after 167 enrolment (n=2), or no positive mRDT at enrolment (n=34) (Figure S1). Thus, the analysis 168 included 589 children with suspected severe malaria, of which 314 (53%) were enrolled by 169 CORPs and 275 (47%) by PHCs (Table 1).

- 170 Children were enrolled from 139 community-based providers in the study area. The number of
- enrolled patients per provider varied from 1 to 42 (median=2, IQR: 2 4), with fewer PHCs
- and a tendency for larger numbers in PHCs. Heterogeneity of almost all variables was high
- 173 within children enrolled by the same health provider.

174 **Patient characteristics**

- 175 Overall, there were more male than female patients in the study and the mean patient age was
- 176 2.0 years. Caregivers were most often female and between the ages of 25 to 34. More children

were enrolled in the rainy season than the dry season. There were no differences in the aforementioned aspects between patients enrolled by CORPs and PHCs (Table 1). Children first attending PHCs were more likely to live in an urban area (adjusted odds ratio [AOR]: 4.6, 95%CI: 1.4 - 15.4) and less likely to visit the facility during a weekend (AOR: 0.5, 95%CI: 0.3 - 0.9). They were also more often enrolled after the introduction of RAS in the study area (AOR: 3.3, 95%CI: 1.7 - 6.4), and during the COVID-19 pandemic (AOR: 1.9, 95%CI: 1.0 - 3.6).

184 **Table 1**. Patient characteristics by type of provider visited

| | CORP | | PH | IC | | | |
|----------------------------------|----------|----------|-----------|----------|------|---------------|--------------|
| | N | % | N | % | AOR* | 95% CI* | p- value* |
| Total | 314 | | 275 | | | | |
| Child sex | | | | | | | |
| Male | 188 | 60 | 164 | 60 | Ref. | | |
| Female | 126 | 40 | 111 | 40 | 1.0 | (0.7 - 1.3) | 0.91 |
| Child age (years) | | | | | | , , | |
| 0 | 40 | 13 | 27 | 10 | Ref. | | 0.34 |
| 1 | 86 | 27 | 74 | 27 | 1.3 | (0.7 - 2.6) | 0.0.1 |
| 2 | 82 | 26 | 82 | 30 | 1.5 | (0.8 - 2.9) | |
| 3 | 68 | 20 | 55 | 20 | 1.3 | . , | |
| | | | | | | (0.6 - 2.4) | |
| 4 | 38 | 12 | 37 | 13 | 1.5 | (0.7 - 3.4) | |
| Caregiver sex | 400 | 00 | 05 | 05 | D.(| | |
| Male | 102 | 32 | 95 | 35 | Ref. | (0, 0, 1, 0) | 0.40 |
| Female | 212 | 68 | 180 | 65 | 0.9 | (0.6 - 1.3) | 0.48 |
| Caregiver age | 40 | 40 | 40 | 47 | D-f | | 0.47 |
| < 25 | 42 | 13 | 46 | 17 | Ref. | (0, 4, -4, 0) | 0.17 |
| 25 - 34 | 167 | 53 | 128 72 | 47 | 0.7 | (0.4 - 1.2) | |
| 35 - 45 ≥ 45 | 75 30 | 24 10 | 28 | 26 10 | 0.8 | (0.5 - 1.5) | |
| | 0 | 0 | 20 | 0 | 0.9 | (0.4 - 1.7) | |
| Missing Caregiver education** | 0 | 0 | 1 | 0 | - | | |
| Never attended school | 54 | 17 | 65 | 24 | Ref. | | 0.77 |
| Primary or lower | 54 15 | 5 | 26 | 24 9 | 1.5 | (0.6 - 3.4) | 0.77 |
| Secondary or higher | 28 | 9 | 44 | 16 | 1.3 | (0.6 - 2.6) | |
| Quranic | 20 | 7 | 39 | 14 | 1.5 | (0.7 - 3.1) | |
| Missing | 195 | 62 | 101 | 37 | - | (0.7 - 3.1) | |
| LGA | 100 | 02 | 101 | 01 | | | |
| Fufore | 143 | 46 | 94 | 34 | Ref. | | 0.02 |
| Mayo-Belwa | 95 | 30 | 154 | 56 | 2.3 | (0.5 - 10.4) | 0.02 |
| Song | 76 | 24 | 27 | 10 | 0.5 | (0.1 - 1.9) | |
| Residence | | | | | 5.0 | (| |
| Rural | 298 | 95 | 227 | 83 | Ref. | | |
| Urban | 14 | 4 | 43 | 16 | 4.6 | (1.4 - 15.4) | 0.01 |
| Missing | 2 | 1 | 5 | 2 | - | / | - |
| Day of enrolment | | | | | | | |
| Workday | 241 | 77 | 239 | 87 | Ref. | | |
| Weekend | 73 | 23 | 36 | 13 | 0.5 | (0.3 - 0.9) | 0.02 |
| | 15 | 20 | 50 | 15 | 0.0 | (0.3 - 0.3) | 0.02 |
| Season | | | | | | | |

| Dry season | 83 | 26 | 66 | 24 | Ref. | | 0.05 |
|---|-----|----|-----|----|------|-------------|-------|
| Rainy season RAS implementation phase | 231 | 74 | 209 | 76 | 1.0 | (0.6 - 1.6) | 0.95 |
| Pre-RAS | 156 | 50 | 61 | 22 | Ref. | | |
| Post-RAS | 158 | 50 | 214 | 78 | 3.3 | (1.7 - 6.4) | <0.01 |
| COVID-19 pandemic | | | | | | | |
| Pre-COVID-19 | 268 | 85 | 207 | 75 | Ref. | | |
| COVID-19 period | 46 | 15 | 68 | 25 | 1.9 | (1.0 - 3.6) | 0.04 |


185 *Logistic regression adjusting for the COVID-19 pandemic, with standard errors clustered at the level of 186 the health care provider. Likelihood ratio test used to calculate p-values for categorical variables. **Data

187 not collected during the entire study period.

188 Signs and symptoms

189 Convulsions (79%) and being unusually sleepy or unconscious (70%) were more common in 190 children visiting a PHC (Figure 1). Together, these two symptoms involving the Central 191 Nervous System (CNS) were reported more frequently in children first visiting a PHC (90%) 192 than in children first visiting a CORP (74%) (AOR: 3.5, 95%CI: 1.9 - 6.1). There was no 193 significant difference in the proportion of children with CNS symptoms during the COVID-19 194 pandemic (79%) compared to prior to the pandemic (82%).

195 Children enrolled at CORPs were more often reported to vomit everything (72%) or be unable to drink or feed anything (64%). Vomiting everything, prolonged fever (≥7 days) and blood in 196 197 the stool were reported significantly more frequently among children first attending a CORP 198 (Figure 1).



199

Figure 1. Signs and symptoms of severity during the child's case of severe illness stratified by first community-based health provider visited. *Considered statistically significant at p<0.05. **Data not collected during the entire study period.

203 Children often presented with multiple symptoms: proportionately more children attending a 204 PHC (50%) had \geq 4 danger signs compared to children taken to a CORP (39%) (p=0.02) (Table 205 2). Danger signs that were often reported together included convulsions and being unusually 206 sleepy/unconscious (CORP: 36%, PHC: 59%), being unusually sleepy/unconscious and not 207 being able to eat/drink (CORP: 39%, PHC: 46%), being unable to eat/drink and being unable 208 to sit/stand (CORP: 35%, PHC: 41%). The following combination of three danger signs was 209 also commonly reported: convulsions, unusually sleepy/unconscious, and unable to eat/drink 210 anything (32% overall, 26% among CORPs visits, 39% among PHC visits).

211 In three-quarters of the cases, caregivers perceived their child's illness to be serious but not 212 fatal with no statistically significant difference between the two compared groups.

| | CORP | | PH | PHC | | | |
|-----------------------------------|------|----|-----|-----|------|-------------|--------------|
| | N | % | N | % | AOR* | 95% CI* | p- value* |
| Total | 314 | | 275 | | | | |
| Number of danger signs *** | 314 | | 275 | | | | |
| 0 - 1 | 52 | 17 | 32 | 12 | Ref. | | 0.02 |
| 2 - 3 | 138 | 44 | 106 | 39 | 1.4 | (0.8 - 2.4) | |
| ≥ 4 | 124 | 39 | 137 | 50 | 2.0 | (1.2 - 3.4) | |
| Perceived severity of the illness | | | | | | | |
| Not fatal | 236 | 75 | 193 | 70 | Ref. | | |
| Fatal | 76 | 24 | 79 | 29 | 1.3 | (0.8 - 2.0) | 0.25 |
| Don't know/Missing | 2 | 1 | 3 | 1 | - | | |

213 Table 2. Number of danger signs and caregiver's perceived severity of the illness

214 *Logistic regression adjusting for the COVID-19 pandemic, with standard errors clustered at the level of 215 the health care provider. Likelihood ratio test used to calculate p-values for categorical variables. **3 216 children were not said to have any danger signs by caregivers at follow-up but health providers noted

217 danger signs at enrolment. ***Only includes danger signs collected across the whole study period.

218 Home treatment

219 Home treatment was more common among patients attending a PHC than those attending a 220 CORP (AOR: 1.5, 95%CI: 1.0 - 2.1) (Table 3). Treatments included modern medicines, 221 traditional medicines or herbs, and washing or sponging to cool the fever. Caregivers who were 222 able to name the medicine most often gave paracetamol (CORP: 85%, PHC: 92%) and 223 occasionally artemether-lumefantrine, the first-line antimalarial drug (CORP: 15%, PHC: 14%). 224 The type of home treatment did not differ between the two groups.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.01.21267130; this version posted December 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

| | CORP | | PHC | | | | |
|---------------------------------|------|----|-----|----|------|--------------|--------------|
| | Ν | % | N | % | AOR* | 95% CI* | p- value* |
| Total | 314 | | 275 | | | | |
| Any home treatment | | | | | | | |
| No | 209 | 67 | 157 | 57 | Ref. | | |
| Yes | 103 | 33 | 116 | 42 | 1.5 | (1.0 - 2.1) | 0.04 |
| Missing | 2 | 1 | 2 | 1 | - | | |
| Actions taken | 103 | | 116 | | | | |
| Traditional medicines/herbs | 22 | 21 | 26 | 22 | 1.1 | (0.5 - 2.2) | 0.86 |
| Tepid sponging | 7 | 7 | 17 | 15 | 2.4 | (0.9 - 6.4) | 0.09 |
| Given medicine | 79 | 77 | 85 | 73 | 0.8 | (0.5 - 1.5) | 0.55 |
| Medicines given (if known) | 67 | | 76 | | | | |
| Artemether-lumefantrine | 10 | 15 | 11 | 14 | 1.0 | (0.3 - 3.2) | 0.99 |
| Oral rehydration solution (ORS) | 1 | 1 | 1 | 1 | 0.8 | (0.1 - 13.4) | 0.89 |
| Paracetamol | 57 | 85 | 70 | 92 | 2.1 | (0.6 - 7.0) | 0.23 |
| Other | 6 | 9 | 5 | 7 | 0.7 | (0.2 - 2.5) | 0.56 |

Table 3. Actions taken at home prior to consulting health providers

*Logistic regression adjusting for the COVID-19 pandemic, with standard errors clustered at the level of

the health care provider.


228 Treatment seeking


Further details on treatment seeking were collected for 264 children who attended a CORP
and 242 who attended a PHC. Of these, 14% of children attending a PHC and 7% of those
attending a CORP had previously been to another provider (AOR: 2.2, 95%CI: 1.1 – 4.4). In
most cases, the previous provider was a chemist/pharmacy/drug shop for both CORP (47%,
9/19) and PHC (71%, 24/34) enrolments (Fisher's test p=0.85).

234 There was no substantial difference overall in treatment seeking delay to the community-based 235 provider between children first visiting CORPs compared to those first visiting PHCs (Figure 236 2A). Across the study period, in children seeing CORPs, 38% of children sought care the same 237 day or the day after becoming ill and 32% sought care 2-3 days after becoming ill. In PHC 238 enrolments, slightly more children went to the enrolling provider 2-3 days after symptom onset 239 (41%) compared to the same day or day after (35%). Home treatment was also associated 240 with delay to a community-based provider. Children seeking care promptly had the lowest rates of home treatment administration (CORP: 18% and PHC: 32%) compared to those with greater 241 242 delays (CORP: 44% and PHC: 52% in delays greater than one day) (p<0.01). The COVID-19 243 pandemic was found to decrease timely treatment seeking (same or following day) to CORPs 244 (AOR: 5.1, 95%CI: 1.8 – 14.3) but not to PHCs (AOR: 1.5, 95%CI: 0.7 – 3.1).


245 PHCs, offering a wider range of services and being much fewer than CORPs, were significantly

- more likely to be located outside the child's village than CORPs (50% vs. 6%; AOR: 18.0,
- 247 95%CI: 6.8 47.2) (Figure 2B).





251 A total of 456 caregivers provided reasons for taking their child to the CORP or the PHC (Figure 252 3). The most common reasons for visiting a CORP were knowing (76%) and trusting (26%) the 253 provider and low cost (22%). In contrast, reasons for attending a PHC included the experience 254 (49%) and medical professionalism (34%) of PHC health workers, as well as knowing the 255 provider (32%). Caregivers who brought their child to a CORP were significantly more likely to 256 list knowing or trusting the provider, and the service being inexpensive as reasons for visiting, 257 whereas those attending a PHC were more likely to list the experience and professionalism of 258 the provider, and an expectation or custom to consult the provider as reasons.



259

260 Figure 3. Odds ratio for reasons caregivers took their child with severe febrile illness to the initial CORP 261 compared to the PHC provider. Logistic regression adjusting for the COVID-19 pandemic, with standard 262 errors clustered at the level of the health care provider.

263 **Discussion**

264 Early diagnosis and prompt effective treatment are critical in the management of malaria to 265 prevent progression to severe disease, lasting disability, and death (4). We previously found 266 that children with suspected severe malaria who first attended a PHC were three times more 267 likely to die than those who visited a CORP (CFR 18.5% vs. 5.7%), a finding that could not be 268 explained by differences in referral delay or post-referral treatment (11). Here, we investigated 269 differences in the characteristics and treatment history of patients relative to their visit to the 270 first community provider (CORP or PHC).

271 There were no differences in the demographic characteristics of patients attending CORPs or 272 PHCs. However, children who first saw PHCs appeared to be more severely ill than those who 273 first saw CORPs as reflected in the presence of CNS danger signs (90% vs. 74%) and the 274 number of reported danger signs. The lack of an expert clinical examination of all patients 275 included in this study limited the extent to which differences in illness severity could be 276 examined, although using presence of CNS symptoms as a proxy for severe disease has been 277 done previously (15-18). Additionally, caregivers were asked about signs and symptoms at any point during their child's complete illness course. Thus, the causal relationship between 278 279 severity and the complexity of disease progression and treatment seeking is difficult to 280 elucidate. Warsame et al. (2016) previously found that children attending community health 281 workers, in settings comparable to ours, had higher rates of CNS symptoms compared to those 282 attending other health providers such as trained mothers or traditional healers, suggesting that

children with more severe symptoms may be more likely to be taken to particular health providers, possibly based on the perceived professional capacity of the providers (18). In Burkina Faso, cases of severe disease often bypass community health workers in favour of a professional health worker (19). Higher degrees of severity among children with severe febrile illness, defined by the symptoms altered consciousness or coma, convulsions, and difficulties in breathing, have also been positively associated with hospital attendance in rural Tanzania (20).

In our study, caregivers mentioned taking children to a PHC for the provider's professionalism and experience. This may be due to the higher illness severity of these children even though this was not reflected in caregiver's reported perception of illness severity. However, this data was quantitatively collected and did not explore multidimensional aspects of perceived severity (eg. emotions, knowledge about severe malaria, economic consequences in seeking or not seeking treatment) (21).

Home treatment was provided slightly more often to children brought to a PHC compared to those brought to a CORP (AOR: 1.5). This treatment consisted in most cases of an antipyretic drug which, on its own, would be counter-productive in the treatment of an episode of severe malaria as it would alleviate symptoms and suggest an improvement of the child's condition. While previous qualitative evidence from Nigeria suggested that children with suspected malaria were usually given paracetamol and an antimalarial or traditional medicine at home (22), home treatment with an antimalarial was uncommon in children in this study.

303 Children attending PHCs were also more likely to have attended another provider, mostly a 304 drug shop/chemist/pharmacy. While such providers may facilitate access to medicines in a 305 similar way as CORPs, attending such a provider may also unnecessarily delay a visit to a 306 health facility. This is particularly problematic when children suffer from an episode of severe 307 malaria (or another severe illness) and the treatment provided at the drug outlet is inadequate.

308 Our study found that approximately two-thirds of children with suspected severe malaria did 309 not attend one of the community-based providers on the day or the day after the onset of 310 symptoms. This may in part explain the overall high CFR seen among children in this study. 311 We did not find a significant difference in treatment seeking delay between patients attending 312 CORPs and PHCs even though the latter were more likely to attend another provider 313 beforehand. On the other hand, during COVID-19 pandemic restrictions on movement 314 imposed by the government, delay in seeking treatment increased substantially among those 315 going to a CORP but only marginally among those attending a PHC. CORPs experienced 316 stockouts of commodities and delay in replenishment during the COVID-19 lockdown (data not 317 shown), which could have contributed to discouraging attendance. Considering the

retrospective assessment of treatment seeking in this study, the recall period of 28 days may
have limited how precisely the time of illness onset and treatment initiation have been
remembered. Smaller changes in treatment delay may hence have remained undetected.

321 Longer delay in attending the first community-based provider was associated with the 322 administration of home treatments. In consideration of the infrequent use of antimalarial 323 medicines at home, any delay in seeking treatment for the episode of suspected severe malaria 324 is therefore likely to have aggravated the severity of the condition. While our study explored 325 treatment seeking delay in number of days, we lack background information on the actual 326 travel time it took and the circumstances of reaching a provider. This may be more relevant in 327 the case of PHCs, which were located outside the patient's village in 50% of the cases (as 328 opposed to 6% for CORPs). A strenuous transport may negatively affect the condition of a 329 severely sick child.

330 Other characteristics may have influenced the choice of first community-based provider without 331 necessarily affecting the observed difference in CFR. In Nigeria, PHCs are not located in the 332 most remote areas, although they are often at a considerable distance from the nearest referral 333 health facility (23). This is reflected in our data where children attending a PHC more often 334 resided in urban areas compared to those attending a CORP. Similarly, Druetz et al. (2015) 335 showed that in rural areas of Burkina Faso, the decision to consult a community health worker 336 for malaria increased with increased distance to the nearest health facility (24). Provider 337 operating hours also affect health-seeking behaviours. PHCs likely have more standard 338 operating hours and certainly do not provide 24-hour service, while CORPs, who are 339 volunteers and may have other jobs or household activities, may have more flexible hours. We 340 found that on weekends, patients rather attended CORPs than PHCs. A different finding was 341 published by Koce et al. (2020) who qualitatively investigated factors influencing self-referral 342 to higher level facilities in Nigeria and demonstrated that the limited staff and operating hours 343 of community-based providers (compared to referral facilities) resulted in patients directly 344 seeking care from higher level facilities (25). Other factors predicting community level provider 345 choice including knowledge of malaria and costs associated with treatment seeking were not 346 assessed.

Taken together, the findings from this analysis suggest that, compared to those attending a CORP, children who first attended a PHC may have been more severely ill, potentially aggravated by inadequate home management, delay in attending the health facility, and possibly a longer and more strenuous travel. Considering that all included children had danger signs of severe illness, caregivers may have underestimated the severity of the child's condition in many cases.

353 Together, these factors may have contributed to a higher CFR among children attending a 354 PHC. Other factors affecting the health outcome of children in this study were investigated in 355 previous analyses. For example, the likelihood of death was higher among children who were 356 treated with pre-referral RAS (AOR: 2.42, 95%CI: 1.25 – 4.70), whereas a higher proportion of 357 children first attending PHCs received RAS compared to those attending CORPs (11). This 358 finding may be related to subsequent referral and treatment patterns rather than to RAS itself. 359 For example, only 48% of children completed referral to a Cottage Hospital after administration 360 of RAS by a CORP or PHC (though those attending a PHC were much more likely to complete referral) (12). Post-referral treatment with an injectable antimalarial was common but few 361 362 children were subsequently treated with the required full course of oral artemisinin-based 363 combination therapy (Signorell et al. manuscript in preparation).

The factors explored in this article in light of other findings are likely to contribute to the high (11.7%) CFR observed in Nigeria but they do not explain the differences between children attending CORPs and those attending PHCs. The higher CFR in those attending a PHC was unexpected since PHCs have higher treatment capacities compared to CORPs.

368 Previous investigations found an increased risk of dying in the period after the roll-out of RAS 369 in the study area (May 2019 to July 2020) (11), which coincided with the period in which more 370 patients first attended a PHC. This finding is unlikely to be related to RAS itself but may have 371 been influenced by circumstantial changes including the emergence of other infectious 372 diseases with similar clinical presentations. Several suspected viral outbreaks occurred in 373 Adamawa State during the study period, including Lassa Fever and Yellow Fever (26, 27). The 374 symptoms of these diseases are often unspecific and overlap with severe malaria. Differential 375 diagnosis of these diseases was not available for the study patients.

376 This study provides insight into differences in background characteristics and care seeking 377 between patients attending different community-based providers in Nigeria, contributing to an 378 explanation of the difference in CFRs between patients attending different community-based 379 health care providers in Nigeria. Additionally, it contributes to the limited literature on care 380 seeking for severely ill children, a population which is comparably small and for which 381 published evidence is scarce (21). While findings from this study may not necessarily be directly applicable to other settings, they point to issues that warrant careful attention when 382 383 promoting the management of severe childhood illness at community level in rural African 384 settinas.

385 Conclusions

This research provides context on treatment seeking for children with suspected severe malaria between community-based health providers in Nigeria to explain the higher CFRs seen in children visiting PHCs compared to those visiting CORPs in the CARAMAL project. The higher illness severity seen in children visiting PHCs as their first community-based provider likely drives the high CFR.

391 List of Abbreviations

- 392 ACT Artemisinin-based Combination Therapy
- 393 AOR Adjusted Odds Ratio
- 394 CARAMAL Community Access to Rectal Artesunate for Malaria
- 395 CFR Case Fatality Rate
- 396 CNS Central Nervous System
- 397 CORP Community Oriented Resource Person
- 398 iCCM integrated Community Case Management
- 399 IMCI Integrated Management of Childhood Illnesses
- 400 LGA Local Government Areas
- 401 mRDT malaria Rapid Diagnostic Test
- 402 PHC Primary Health Center
- 403 RAS Rectal Artesunate
- 404 WHO World Health Organization

405 Acknowledgements

- 406 We would like to acknowledge the children and their caregivers who participated in the study
- 407 and the large number of community health providers, data collectors, local coordinators, local
- 408 CHAI, UNICEF, and WHO colleagues who made this work possible. We additionally would like
- 409 to thank Amanda Ross for her statistical support.

410 **Declarations**

411 Ethics approval and consent to participate

- The CARAMAL study protocol was approved by the Research Ethics Review Committee of the World Health Organization (WHO ERC, No. ERC.0003008), the Health Research Ethics Committee of the Adamawa State Ministry of Health (S/MoH/1131/I), the National Health Research Ethics Committee of Nigeria (NHREC/01/01/2007-05/05/2018), and the Scientific
- and Ethical Review Committee of CHAI (No. 112, 21 Nov 2017). The study is registered on
- 417 ClinicalTrials.gov (NCT03568344). Provisional verbal informed consent was obtained from
- 418 caregivers by the community-based provider, while full written informed consent was obtained
- 419 during a follow-up contact at a referral facility or on day 28. Only patients whose caregivers
- 420 provided written informed consent were officially enrolled in the study.

421 **Consent for publication**

422 Not applicable. Results not linkable to individual participants.

423 Availability of data and materials

The datasets generated during and/or analysed during the current study are available in the Zenodo repository, (DOI: 10.5281/zenodo.5733006), upon reasonable request to the corresponding author.

427 Competing interests

- 428 None declared.
- 429 Funding
- 430 This study was funded by Unitaid.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.01.21267130; this version posted December 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

431 **References**

Kendjo E, Agbenyega T, Bojang K, Newton CR, Bouyou-Akotet M, Pedross F, et al.
 Mortality patterns and site heterogeneity of severe malaria in African children. PLoS One.
 2013;8(3):e58686.

435 2. Bassat Q, Guinovart C, Sigaúque B, Aide P, Sacarlal J, Nhampossa T, et al. Malaria in 436 rural Mozambique. Part II: children admitted to hospital. Malar J. 2008;7:37.

3. Orimadegun AE, Fawole O, Okereke JO, Akinbami FO, Sodeinde O. Increasing burden
of childhood severe malaria in a Nigerian tertiary hospital: implication for control. J Trop
Pediatr. 2007;53(3):185-9.

440 4. World Health Organization. Guidelines for the treatment of malaria – 3rd edition. 2015.
441 5. Consortium HEFD. Integrated Community Case Management (iCCM) in Sub-Saharan
442 Africa: Successes & Challenges with Access, Speed & Quality. September 2018. Health
443 Economic Finance Development Consortium; 2018.

444 6. Strides Shasun's rectal artesunate product receives WHO prequalification.
 445 <u>https://www.mmv.org/newsroom/news/strides-shasun-s-rectal-artesunate-product-receives-</u>
 446 who-prequalification. Accessed August 23, 2021.

Gomes MF, Faiz MA, Gyapong JO, Warsame M, Agbenyega T, Babiker A, et al. Prereferral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled
trial. Lancet. 2009;373(9663):557-66.

450 8. World Health Organization. World malaria report 2020: 20 years of global progress and
451 challenges. Geneva: World Health Organization; 2020. Report No.: Licence: CC BY-NC-SA
452 3.0 IGO.

453 9. Welcome MO. The Nigerian health care system: Need for integrating adequate medical
454 intelligence and surveillance systems. J Pharm Bioallied Sci. 2011;3(4):470-8.

455 10. Federal Ministry of Health. National Guidelines for Diagnosis and Treatment of Malaria456 (Third Edition). Abuja; 2015.

Hetzel MW, Okitawutshu J, Tshefu A, Omoluabi E, Awor P, Signorell A, et al.
Effectiveness of rectal artesunate as pre-referral treatment for severe malaria in children <5
years of age. Preprint at https://doi.org/10.1101/2021.09.24.21263966 (2021).

Brunner NC, Omoluabi E, Awor P, Okitawutshu J, Tshefu A, Signorell A, et al. Prereferral rectal artesunate and referral completion among children with suspected severe
malaria in the Democratic Republic of the Congo, Nigeria and Uganda. Preprint at
<u>https://doi.org/10.1101/2021.09.27.21264073</u> (2021).

464 13. WorldPop. World Population Demographics: Subnational Age/Sex Structures - 2000465 2020. <u>https://www.portal.worldpop.org/demographics/</u>. Accessed July 6, 2021.

466 14. Weber EM, Seaman VY, Stewart RN, Bird TJ, Tatem AJ, McKee JJ, et al. Census467 independent population mapping in northern Nigeria. Remote Sens Environ. 2018;204:786-98.
468 15. Simba DO, Warsame M, Kimbute O, Kakoko D, Petzold M, Tomson G, et al. Factors

influencing adherence to referral advice following pre-referral treatment with artesunate
suppositories in children in rural Tanzania. Trop Med Int Health. 2009;14(7):775-83.

471 16. Siribié M, Ajayi IO, Nsungwa-Sabiiti J, Sanou AK, Jegede AS, Afonne C, et al.
472 Compliance With Referral Advice After Treatment With Prereferral Rectal Artesunate: A Study
473 in 3 Sub-Saharan African Countries. Clin Infect Dis. 2016;63(suppl 5):S283-s9.

474 17. Ajayi IO, Nsungwa-Sabiiti J, Siribié M, Falade CO, Sermé L, Balyeku A, et al. Feasibility
475 of Malaria Diagnosis and Management in Burkina Faso, Nigeria, and Uganda: A Community476 Based Observational Study. Clin Infect Dis. 2016;63(suppl 5):S245-s55.

477 18. Warsame M, Gyapong M, Mpeka B, Rodrigues A, Singlovic J, Babiker A, et al. Pre478 referral Rectal Artesunate Treatment by Community-Based Treatment Providers in Ghana,
479 Guinea-Bissau, Tanzania, and Uganda (Study 18): A Cluster-Randomized Trial. Clin Infect
480 Dis. 2016;63(suppl 5):S312-s21.

481 19. Sauerborn R, Nougtara A, Diesfeld HJ. Low utilization of community health workers:
482 results from a household interview survey in Burkina Faso. Soc Sci Med. 1989;29(10):1163483 74.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.01.21267130; this version posted December 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

20. Castellani J, Mihaylova B, Evers SM, Paulus AT, Mrango ZE, Kimbute O, et al. Out-ofpocket costs and other determinants of access to healthcare for children with febrile illnesses:
a case-control study in rural Tanzania. PLoS One. 2015;10(4):e0122386.

487 21. Brunner N, Awor P, Hetzel M. Definitions of Severity in Treatment Seeking Studies of
488 Febrile Illness in Children in Low and Middle Income Countries: A Scoping Review.
489 International Journal of Public Health. 2021;66(74).

490 22. Elimian KO, Myles PR, Phalkey R, Sadoh A, Pritchard C. 'Everybody in Nigeria is a
491 doctor...': a qualitative study of stakeholder perspectives on lay diagnosis of malaria and
492 pneumonia in Nigeria. J Public Health (Oxf). 2020;42(2):353-61.

493 23. Kuupiel D, Adu KM, Bawontuo V, Mashamba-Thompson TP. Geographical
494 Accessibility to District Hospitals/Medical Laboratories for Comprehensive Antenatal Point-of495 Care Diagnostic Services in the Upper East Region, Ghana. EClinicalMedicine. 2019;13:74496 80.

497 24. Druetz T, Ridde V, Kouanda S, Ly A, Diabaté S, Haddad S. Utilization of community
498 health workers for malaria treatment: results from a three-year panel study in the districts of
499 Kaya and Zorgho, Burkina Faso. Malar J. 2015;14:71.

500 25. Koce FG, Randhawa G, Ochieng B. A qualitative study of health care providers' 501 perceptions and experiences of patients bypassing primary healthcare facilities: a focus from 502 Nigeria. Journal of Global Health Reports. 2020.

503 26. World Health Organization. Yellow Fever – Nigeria. Accessed October 19, 2021.

504 27. Agbonlahor DE, Akpede GO, Happi CT, Tomori O. 52 Years of Lassa Fever Outbreaks

505 in Nigeria, 1969-2020: An Epidemiologic Analysis of the Temporal and Spatial Trends. Am J 506 Trop Med Hyg. 2021.

507